Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract C103: Targeting IL-1β pathway for cancer immunotherapy

Pushpa Jayaraman, John Millholland, Neil O’Brien, Connie Wong, Rohan Diwanji, Muchun Wang, Elizabeth Choi, Ronald Linnartz, Kristine Rose, Vanessa Rodrik-Outmezguine, Marc Pelletier, Alexander Savchenko, Tong Luo, Valerie Rezek, Scott Kitchen, Jason Baum, Catherine Sabatos-Peyton, Anne-Marie Martin, Glenn Dranoff

Mol Cancer Ther (2019) 18 (12_Supplement): C103.

https://doi.org/10.1158/1535-7163.TARG-19-C103

Published: 01 December 2019

View article titled, Abstract C103: Targeting IL-1β pathway for cancer immunotherapy

Journal Articles

Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

Li Liu, Hong Shi, Yuan Liu, Amber Anderson, John Peterson, James Greger, Anne-Marie Martin, Tona M. Gilmer

Mol Cancer Ther (2011) 10 (3): 518–530.

https://doi.org/10.1158/1535-7163.MCT-10-0698

Published: 08 March 2011

View article titled, Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

Includes: Supplementary data

Journal Articles

Abstract A238: The effects of foretinib on MET phosphorylation, gene expression, cell proliferation and tumor growth in MET‐amplified tumor cells in vitro and in vivo

Li Liu, Yuan Liu, Shi Hong, James Greger, Anne‐Marie Martin, Tona Gilmer

Mol Cancer Ther (2009) 8 (12_Supplement): A238.

https://doi.org/10.1158/1535-7163.TARG-09-A238

Published: 10 December 2009

View article titled, Abstract A238: The effects of foretinib on MET phosphorylation, gene expression, cell proliferation and tumor growth in MET‐amplified tumor cells in vitro and in vivo

Journal Articles

Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients

Fabiola Cecchi, Yuan Liu, Robert C. Gagnon, Howard Kallender, Daniel C. Rabe, Manish A. Shah, Anne‐Marie Martin, Donald P. Bottaro

Mol Cancer Ther (2009) 8 (12_Supplement): B210.

https://doi.org/10.1158/1535-7163.TARG-09-B210

Published: 10 December 2009

View article titled, Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients

Journal Articles

Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL‐6, and IL‐8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib

John V. Heymach, Hai T. Tran, Herbert A. Fritsche, Terrie G. Gornet, Yuan Liu, Dilip Rajagopalan, Anne‐Marie Martin, Katherine L. Baker, Louise Downie, Thomas E. Hutson, Robert A. Figlin, VEG102616 Team, Rafael G. Amado, Lini N. Pandite

Mol Cancer Ther (2009) 8 (12_Supplement): A11.

https://doi.org/10.1158/1535-7163.TARG-09-A11

Published: 10 December 2009

View article titled, Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL‐6, and IL‐8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib

Journal Articles

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

Joel Greshock, Jie Cheng, David Rusnak, Anne Marie Martin, Richard Wooster, Tona Gilmer, Kwan Lee, Barbara L. Weber, Tal Zaks

Mol Cancer Ther (2008) 7 (4): 935–943.

https://doi.org/10.1158/1535-7163.MCT-07-2072

Published: 15 April 2008

View article titled, Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

Includes: Supplementary data

Journal Articles

Characterizing response to lapatinib (GW572016) in non-Her2 amplified tumor-derived cell lines

Joel greshock, William Cornwell, Yan Degenhardt, Kurtis Bachman, Christopher Moy, David Rusnak, Anne-Marie Martin, Tona Gilmer, Jie Cheng, Kwan Lee, Tal Zaks, Barbara Weber, Richard Wooster

Mol Cancer Ther (2007) 6 (11_Supplement): C142.

Published: 01 November 2007

View article titled, Characterizing response to lapatinib (GW572016) in non-Her2 amplified tumor-derived cell lines

NARROW

Abstract C103: Targeting IL-1β pathway for cancer immunotherapy

Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

Abstract A238: The effects of foretinib on MET phosphorylation, gene expression, cell proliferation and tumor growth in MET‐amplified tumor cells in vitro and in vivo

Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients

Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL‐6, and IL‐8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

Characterizing response to lapatinib (GW572016) in non-Her2 amplified tumor-derived cell lines

Email alerts

AACR Journals

Abstract C103: Targeting IL-1β pathway for cancer immunotherapy

Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

Abstract A238: The effects of foretinib on MET phosphorylation, gene expression, cell proliferation and tumor growth in MET‐amplified tumor cells in vitro and in vivo

Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients

Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL‐6, and IL‐8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

Characterizing response to lapatinib (GW572016) in non-Her2 amplified tumor-derived cell lines

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only